Abstract:Heat shock protein 90 (HSP90) has emerged as an important target in cancer treatment because many of its clients are crucial in malignant transformation. HSP90 inhibitors such as antibiotic anismycin Geldanamycin and its derivatives 17-AAG promote degradation of client proteins. Several preclinical observations have made HSP90 inhibitors attractive drugs to the treatment of cancer. First, HSP90 inhibitors may provide a broader and effective anticancer therapy. Second, HSP90 in tumor cells was shown to exhibit much higher affinity for its inhibitors. HSP90 inhibitors such as 17-AAG and 17-DMAG are currently used targeting a variety of tumors in clinical trials. The TGFβ signaling pathway represents a major tumor suppressor pathway in normal epithelial cells, and paradoxically, it also acts as a significant promoter of tumor progression, invasion and metastasis in carcinomas. Since tumors are often detected in late stages, inhibition of TGFβ signaling pathway may be beneficiary to cancer patients. Several attempts in the past several years have highlighted the potential of blocking TGFβ responses in tumors by using soluble TGFβ receptors or competitive small molecules targeting the TGFβ receptors in anti-cancer therapy. Notably, the toxicity of TGFβ inhibition is well tolerated in mouse models, suggesting the strong potential of anti-TGFβ therapeutics in cancer. Our recent identification that TGFβ receptors are client proteins of HSP90 provides novel insights into the potential of HSP90 inhibitors in anti-cancer therapies. Objective: (1) To elucidate the molecular mechanisms underlying essential role of HSP90 in controlling TGFβ signaling in normal and cancer cells; (2) To explore the potential of HSP90 inhibitors as anti-metastasis therapeutics in breast cancer. Methods: Using a proteomic approach, we found an association between HSP90 and TGFβ receptors (both TβRI and TβRII). Further TβR-HSP90 interaction, TβR turnover and Smad2 phosphorylation were carried out using immunoprecipitation and western blotting. Dosage and duration of treatment with HSP90 inhibitors GA, 17-AAG, and Ridicicol were initially established by evaluating the blockade of TGFβ-induced Smad2 phosphorylation. Effect of HSP90 inhibitors and HSP90 siRNAs on the expression of TGFβ target gene transcription will be assessed by real-time RT-PCR. Cell proliferation was assayed by 3H-thymidine incorporation, and cell invasiveness was done in BD Matrigel Invasion Chambers in MDA-MB-231 breast carcinoma cells. Results: Using biochemical assays, we confirmed that TGFβ receptors (both TβRI and TβRII) physically associated with HSP90 proteins in a variety of normal and cancer cells. We next found that inhibition of HSP90 functions by several HSP90 inhibitors can promote the rapid turnover of TGFβ receptors in a ubiquitination/proteasome-dependent manner. Consequently, HSP90 inhibitors inhibit TGFβ-mediated phosphorylation of tumor suppressors SMAD2 and SMAD3, and block TGFβ-dependent transcription of genes such as MMP9. At the cellular level, HSP90 inhibitors led to the blockade of TGFβ-induced invasiveness of MDA-MB-231 breast carcinoma cells. Conclusion: We have identified HSP90 inhibitors as potential drugs blocking TGFβ functions. This study should help to understand the mechanisms of TGFβ and HSP90 interplay in progression of human cancers. Our study will also provide invaluable information on the use of HSP90 inhibitors for the treatment of human cancers.

Inhibition of the Heat Shock Protein receptor CD91 abrogate concomitant anti-tumor immunity (127.24)

HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells

Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity

Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell

HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors

The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment

QS288. Potent Blockade of TGF-β Signaling by HSP90 Inhibitors

Caspase-9 inhibition triggers Hsp90-based chemotherapy-mediated tumor intrinsic innate sensing and enhances antitumor immunity

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Tumor-derived Hsp70-CD14 interaction enhances the antitumor potential of cytotoxic T cells by activating tumor-associated macrophages to express CC chemokines and CD40 costimulatory molecules

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

HSF1 inhibits antitumor immune activity in breast cancer by suppressing CCL5 to block CD8+ T cell recruitment.

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials

Dual targeting of CTLA-4 and CD47 on T<sub>reg</sub> cells promotes immunity against solid tumors

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers

Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy

Abstract 4606: Heat shock proteins in immunosuppressive tumor microenvironment

Concurrent Intratumoural Treg Cell Depletion and CD8+ T Cell Expansion Via a Cleavable Anti-4-1bb-interleukin-15 Fusion Protein.